The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
Open accessAbstract
This review provides insights on the impact of glycosylation in cancer biology and its influence in the current approaches of targeted cancer therapies in the clinical setting. The roles of glycosylation in cancer signaling, tumor progression, and metastasis are reviewed as well as glycans and glycan-binding proteins in tumor immunomodulation. Moreover, the latest reports on glycans influencing targeted therapeutic approaches in cancer are summarized. Finally, we discuss the future challenges of the field, outlining potential applications of glycan-based biomarkers for patient stratification and strategies for improving personalized cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycosylation in cancer: mechanisms and clinical implications
Pinho, S. S., & Reis, C. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3982 · Cited by 3,083
Self-citationSiglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031
Precision Medicine — Personalized, Problematic, and Promising
Jameson, J. L., & Longo, D. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmsb1503104 · Cited by 1,106
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Lau, K. S., Partridge, E. A., Grigorian, A., Silvescu, C. I., Reinhold, V. N., Demetriou, M., & Dennis, J. W. (2007) · Cell · doi:10.1016/j.cell.2007.01.049 · Cited by 914
Bennett, E. P., Mandel, U., Clausen, H., Gerken, T. A., Fritz, T. A., & Tabak, L. A. (2012) · Glycobiology · doi:10.1093/glycob/cwr182 · Cited by 876
Regulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis
Partridge, E. A., Le Roy, C., Di Guglielmo, G. M., Pawling, J., Cheung, P., Granovsky, M., Nabi, I. R., Wrana, J. L., & Dennis, J. W. (2004) · Science · doi:10.1126/science.1102109 · Cited by 735
The cancer glycocalyx mechanically primes integrin-mediated growth and survival
Paszek, M. J., DuFort, C. C., Rossier, O., Bainer, R., Mouw, J. K., Godula, K., Hudak, J. E., Lakins, J. N., Wijekoon, A. C., Cassereau, L., et al. (2014) · Nature · doi:10.1038/nature13535 · Cited by 699
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 602
Posey, A. D., Schwab, R. D., Boesteanu, A. C., Steentoft, C., Mandel, U., Engels, B., Stone, J. D., Madsen, T. D., Schreiber, K., Haines, K. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.014 · Cited by 594
Cited by
Pattern recognition receptors in health and diseases
Li, D., & Wu, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00687-0 · Cited by 1,787
Global view of human protein glycosylation pathways and functions
Schjoldager, K. T., Narimatsu, Y., Joshi, H. J., & Clausen, H. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00294-x · Cited by 1,309
Cox, T. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00329-7 · Cited by 976
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics
Thomas, D., Rathinavel, A. K., & Radhakrishnan, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188464 · Cited by 372
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Targeting Glycosylation: A New Road for Cancer Drug Discovery
Costa, A. F., Campos, D., Reis, C. A., & Gomes, C. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.04.002 · Cited by 263
Self-citationPathological implication of protein post-translational modifications in cancer
Pan, S., & Chen, R. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101097 · Cited by 263
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Glutamine deprivation triggers NAGK-dependent hexosamine salvage
Campbell, S., Mesaros, C., Izzo, L., Affronti, H., Noji, M., Schaffer, B. E., Tsang, T., Sun, K., Trefely, S., Kruijning, S., et al. (2021) · eLife · doi:10.7554/elife.62644 · Cited by 58
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
Qusairy, Z., & Rada, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05303-1 · Cited by 16
Unraveling the glycosylated immunopeptidome with HLA-Glyco
Bedran, G., Polasky, D. A., Hsiao, Y., Yu, F., da Veiga Leprevost, F., Alfaro, J. A., Cieslik, M., & Nesvizhskii, A. I. (2023) · Nature Communications · doi:10.1038/s41467-023-39270-2 · Cited by 15
Osteopontin in Cancer: Mechanisms and Therapeutic Targets
Kariya, Y., & Kariya, Y. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2030033 · Cited by 14
Yingli, H., Ping, Y., Jun, Y., & Xingwang, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167853 · Cited by 7
Metadata
- Authors
- Mereiter, S., Balmaña, M., Campos, D., Gomes, J., & Reis, C. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 36
- Issue
- 1
- Pages
- 6-16
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2960011166
- Cited by
- 565
- References
- 78
- FWCI
- 16.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.